MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-26-2026
22nd Century Group ROA Ratio 2011-2026 | XXII
Annual ROA Ratio 22nd Century Group
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -18.7 | -69.97 | -511.85 | -52.16 | -6.62 | -38.13 | -38.52 | -10.31 | -16.34 | -41.9 | -60.05 | -71.04 | -212.86 | -254.65 | -56.68 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -6.62 | -511.85 | -97.32 |
Quarterly ROA Ratio 22nd Century Group
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -32.78 | -64.09 | -53.49 | -42.28 | -155.56 | -254.49 | -266.3 | -144.36 | -153.57 | -49.51 | -42.7 | -32.26 | -43.17 | -44.88 | -39.55 | -23.64 | -36.03 | -33.28 | -38.77 | -38.13 | -34.73 | -41.42 | -43.3 | -38.52 | -41.07 | -18.05 | -15.11 | -10.31 | -3.45 | -15.77 | -11.26 | -16.34 | -21.59 | -27.13 | -33.42 | -41.9 | -47.56 | -52.95 | -49.5 | -60.23 | -70.1 | -67.42 | -69.33 | -71.04 | -170.69 | -283.39 | -278.07 | -149.2 | -166.17 | -58.03 | -49.04 | -91.87 | -111.34 | -113.84 | -165.25 | -92.7 | -19.47 | -46.05 | -27.18 |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -3.45 | -283.39 | -73.1 |
ROA Ratio of other stocks in the Biotechnology industry
| Issuer | ROA Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-20.13 | - | 2.43 % | $ 254 M |  Germany |
 |
Alterity Therapeutics Limited
ATHE
|
-31.06 | $ 3.97 | 6.43 % | $ 9.55 B |  Australia |
 |
Adverum Biotechnologies
ADVM
|
-72.8 | - | - | $ 86.2 M |  USA |
 |
Akouos
AKUS
|
-31.09 | - | 0.23 % | $ 488 M | USA |
 |
I-Mab
IMAB
|
7.43 | - | - | $ 866 M |  China |
 |
AlloVir
ALVR
|
-35.68 | - | 4.14 % | $ 49.1 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
3.33 | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
23.87 | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
-89.6 | - | -13.47 % | $ 169 M | France |
 |
Akari Therapeutics, Plc
AKTX
|
-36.12 | $ 5.12 | 11.55 % | $ 345 B |  Britain |
 |
Aligos Therapeutics
ALGS
|
-27.33 | $ 7.66 | 3.23 % | $ 75.7 M | USA |
 |
Allakos
ALLK
|
-76.23 | - | - | $ 28.6 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-53.39 | - | -1.52 % | $ 24.7 M | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
6.32 | $ 320.13 | -3.98 % | $ 41.9 B | USA |
 |
Midatech Pharma plc
MTP
|
-42.28 | - | -18.52 % | $ 27.3 M | Britain |
 |
Applied Molecular Transport
AMTI
|
-117.57 | - | - | $ 10.1 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
6.02 | $ 21.81 | 0.6 % | $ 1.02 B | USA |
 |
Burford Capital Limited
BUR
|
5.51 | $ 4.67 | -1.37 % | $ 766 M | Britain |
 |
Applied Therapeutics
APLT
|
-218.41 | - | - | $ 8.42 M | USA |
 |
BioNTech SE
BNTX
|
65.02 | $ 102.12 | 2.66 % | $ 27.2 B | Germany |
 |
Aptinyx
APTX
|
-97.25 | - | -39.0 % | $ 4.57 M | USA |
 |
Aravive
ARAV
|
-122.8 | - | -13.39 % | $ 1.45 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
4.82 | - | - | - |  Russia |
 |
Advaxis
ADXS
|
-289.96 | - | -9.65 % | $ 45.9 M | USA |
 |
Aeterna Zentaris
AEZS
|
-10.45 | - | 5.93 % | $ 314 M |  Canada |
 |
Can-Fite BioPharma Ltd.
CANF
|
-103.3 | $ 3.08 | -4.94 % | $ 5.07 M |  Israel |
 |
AgeX Therapeutics
AGE
|
-275.96 | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-19.95 | - | - | $ 1.01 B | USA |
 |
Akebia Therapeutics
AKBA
|
-1.42 | $ 1.35 | -12.9 % | $ 347 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-489.29 | - | - | $ 7.46 M | Israel |
 |
Applied Genetic Technologies Corporation
AGTC
|
-27.57 | - | - | $ 26.5 M | USA |
 |
Aquestive Therapeutics
AQST
|
-52.23 | $ 4.26 | 0.47 % | $ 456 M | USA |
 |
AstraZeneca PLC
AZN
|
0.11 | - | - | $ 96.9 B | Britain |
 |
Arcutis Biotherapeutics
ARQT
|
-3.73 | $ 24.19 | -1.59 % | $ 3.08 B | USA |
 |
AIkido Pharma
AIKI
|
-19.87 | - | 1.93 % | $ 17.4 M | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
-1008.51 | - | -2.5 % | $ 5.88 M | USA |
 |
BioDelivery Sciences International
BDSI
|
26.14 | - | -4.8 % | $ 255 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
-48.81 | $ 1.61 | 8.05 % | $ 428 M | Britain |
 |
Aptose Biosciences
APTO
|
-254.37 | - | -45.71 % | $ 1.2 M | Canada |
 |
AVROBIO
AVRO
|
12.03 | - | 1083.1 % | $ 745 M | USA |
 |
BeiGene, Ltd.
BGNE
|
3.5 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
bluebird bio
BLUE
|
-34.23 | - | - | $ 546 M | USA |
 |
Akero Therapeutics
AKRO
|
-30.52 | - | - | $ 3.67 B | USA |
 |
CureVac N.V.
CVAC
|
-35.55 | - | - | $ 867 M | Germany |
 |
Cidara Therapeutics
CDTX
|
-79.06 | - | - | $ 1.41 B | USA |
 |
BioXcel Therapeutics
BTAI
|
-155.62 | $ 1.07 | 1.9 % | $ 13.1 M | USA |
 |
Cabaletta Bio
CABA
|
-101.68 | $ 3.52 | 3.53 % | $ 354 M | USA |
 |
CymaBay Therapeutics
CBAY
|
-24.24 | - | - | $ 3.45 B | USA |
 |
Allena Pharmaceuticals
ALNA
|
-140.01 | - | 3.16 % | $ 1.9 M | USA |
 |
ChromaDex Corporation
CDXC
|
16.34 | - | -0.88 % | $ 598 M | USA |